Selected article for: "administration result and low toxicity"
Title: 2016 ACVIM Forum Research Abstract Program
  • Document date: 2016_5_31
    • ID: 2y1y8jpx_195
    Snippet: Three fraction SRT has been used to treat non-lymphomatous nasal tumors in 25 dogs with limited adverse events. Continued accrual and follow-up will be necessary to confirm low toxicity, further elucidate effects of stage on outcome, and characterize clinical efficacy. Osteosarcoma (OSA) is locally invasive and highly metastatic. We hypothesize that standard-of-care carboplatin chemotherapy followed by continued administration of toceranib phosph.....
    Document: Three fraction SRT has been used to treat non-lymphomatous nasal tumors in 25 dogs with limited adverse events. Continued accrual and follow-up will be necessary to confirm low toxicity, further elucidate effects of stage on outcome, and characterize clinical efficacy. Osteosarcoma (OSA) is locally invasive and highly metastatic. We hypothesize that standard-of-care carboplatin chemotherapy followed by continued administration of toceranib phosphate (TP) will result in improved survival in dogs with OSA as compared to historical controls that did not receive TP. In addition, we hypothesize that TP will decrease circulating levels of pro-angiogenic MMP-9, a downstream factor and surrogate marker for VEGF receptor inhibition.

    Search related documents:
    Co phrase search for related documents
    • adverse event and clinical efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adverse event and historical control: 1, 2, 3, 4
    • adverse event and improve survival: 1, 2
    • adverse event and limited adverse event: 1, 2
    • adverse event and low toxicity: 1
    • care standard and clinical efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • care standard and downstream factor: 1
    • care standard and historical control: 1, 2, 3
    • care standard and improve survival: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • care standard and low toxicity: 1, 2, 3
    • clinical efficacy and continue administration: 1
    • clinical efficacy and improve survival: 1, 2, 3, 4
    • clinical efficacy and low toxicity: 1, 2, 3, 4, 5, 6, 7, 8
    • improve survival and low toxicity: 1, 2